Last reviewed 2026-04-19 · How we verify

IPTi mefloquine

London School of Hygiene and Tropical Medicine · Phase 2 active Small molecule

IPTi mefloquine is a Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 2 development. Also known as: Larium.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	IPTi mefloquine
Also known as	Larium
Sponsor	London School of Hygiene and Tropical Medicine
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Kilimanjaro IPTi Drug Options Trial (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IPTi mefloquine CI brief — competitive landscape report
IPTi mefloquine updates RSS · CI watch RSS
London School of Hygiene and Tropical Medicine portfolio CI

Frequently asked questions about IPTi mefloquine

What is IPTi mefloquine?

IPTi mefloquine is a Small molecule drug developed by London School of Hygiene and Tropical Medicine.

Who makes IPTi mefloquine?

IPTi mefloquine is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

Is IPTi mefloquine also known as anything else?

IPTi mefloquine is also known as Larium.

What development phase is IPTi mefloquine in?

IPTi mefloquine is in Phase 2.

Manufacturer: London School of Hygiene and Tropical Medicine — full pipeline
Also known as: Larium

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing